Subcutaneous (subQ or SQ) injections are shots given in the fatty tissue layer (subcutaneous fat) under your skin. Your skin has many layers, and the subcutaneous layer is beneath the epidermis and ...

Subcutaneous immunotherapy injections work the same way as their intravenous counterparts — by changing or enhancing a person’s immune responses to cancer. Immunotherapy for cancer is a broad category ...

Subcutaneous injection of the immunotherapy nivolumab (brand name Opdivo) is noninferior to intravenous delivery and dramatically reduces treatment time in patients with renal cell carcinoma, as seen ...

Incidence and risk factors for central nervous system (CNS) metastasis (met) in patients (pts) with stage III melanoma treated with adjuvant (ADJ) anti-PD1 immunotherapy (IMT). This is an ASCO Meeting ...

Sanofi’s Sarclisa subcutaneous approved in the EU as the first anticancer treatment administered via an on-body injectorSarclisa administered via ...

Somatuline Depot (lanreotide) is a brand-name drug prescribed for acromegaly, certain cancers, and carcinoid syndrome in adults. Somatuline Depot is given as a subcutaneous injection by a healthcare ...

High complete response rate with TNB-486 in relapsed/refractory follicular lymphoma: Interim results from an ongoing phase 1 study. Outcomes for pts with CR (n=62).

IV therapy delivers cancer medicine directly into a vein and often requires a longer infusion visit at a clinic or hospital. Subcutaneous therapy is an injection given under the skin and usually takes ...

Monash University researchers, alongside key partner Halozyme Therapeutics, report findings in support of shifting the way anti-cancer immunotherapy is administered from intravenous administration to ...

The GLP-1 era has already reshaped cardiovascular outcomes, weight management, and diabetes care. Now the field is entering its next phase — oral formulations. (Medscape) Early uptake has been ...

BHV-1300 achieved deep lowering of targeted IgG, with reductions > 60% in the lowest subcutaneous dose tested in the MAD. Subcutaneous BHV-1300 achieved rapid and progressive lowering of IgG within ...